

01/07/2026

NN-ICB/26-1631

Dear Requestor

Re: Freedom of Information Request

Thank you for your request for information, received on 27 May 2026, regarding dermatology services and the use of teledermatology. We have processed your request in accordance with the Freedom of Information Act 2000 (FOIA).

Under the FOIA, public authorities like ours are required to respond to requests for information within 20 working days. In response to your request, I can confirm that we partially hold the information requested.

Please find below our response to your request:

1. Dermatology referral activity

Please provide data for the last 3 full financial years on the following for your ICB:

- The total number of new referrals onto a dermatology Referral to Treatment (RTT) pathway
[Statistics » Consultant-led Referral to Treatment Waiting Times Data 2026-27](#)

Please find below Dermatology Referrals for the last 3 financial years as a total, but also split down into the Referral Priority to get the two-week wait sub-set:

	2023/24		2024/25		2025/26		Total Count	Total %
Referral Priority	Count	%	Count	%	Count	%		
Routine	14509	54.3%	16492	56.2%	10785	39.7%	41786	50.2%
Two Week Wait	6552	24.5%	6184	21.1%	8788	32.4%	21524	25.9%
Urgent	4746	17.8%	5618	19.1%	4413	16.2%	14777	17.7%
Unknown	926	3.5%	1060	3.6%	3179	11.7%	5165	6.2%
Grand Total	26733	100.00%	29354	100.00%	27165	100.00%	83252	100.00%

For further details, please also refer to the national link - [Statistics » Consultant-led Referral to Treatment Waiting Times Data 2026-27](#).

- The total number of urgent suspected cancer (two-week wait) referrals for skin cancer

The ICB does not hold this information - see below.

- The total number of skin cancers diagnosed

The ICB does not hold this information.

Regarding two-week wait referrals for skin cancer and total number of skin cancers diagnosed, the ICB does not receive outcome data for these categories.

As a guide, the Fingertips website publish the skin cancer referrals and the total number of cancer diagnosis at the following link: [Fingertips | Department of Health and Social Care](#), which you may find useful.

This shows for all Cancer Tumour Sites in 2024/25, 6.3% of all referrals resulted in a confirmed cancer diagnosis, for Skin Cancer a proxy diagnosis rate shows 10.5% of referrals result in a Skin Cancer diagnosis using local data.

For further details, please also refer to the national link - [Statistics » Cancer Waiting Times](#).

For further details, please contact individual providers and how to submit a Freedom of Information request to each provider can be found on their website links below:

- Nottingham University Hospitals NHS Trust - <https://www.nuh.nhs.uk/freedom-of-information>
- Sherwood Forest Hospitals NHS Foundation Trust - [Freedom of Information | Sherwood Forest Hospitals](#).

2. Community dermatology provision

Does your ICB currently commission a community dermatology service, separate from acute trust-based provision?

Yes.

If yes, please state:

- The name of the organisation or organisations providing it

The ICB commissions a community dermatology service across four providers: Bilsthorpe Surgery, HealthHarmonie, Radcliffe on Trent Health Centre, and Ozone.

- Whether the service includes a teledermatology component

This services does not include a teledermatology component.

3. Teledermatology commissioning status

Does your ICB currently commission a teledermatology service?

Yes.

If yes:

- Please confirm whether this is commissioned as a standalone service or as part of a wider community dermatology or dermatology pathway contract.

The community teledermatology service is commissioned as a standalone service.

- Please state the name of the organisation or organisations currently providing the teledermatology service

The community teledermatology service is currently provided by Ozone.

- Please state the start date, end date, and total contract value of the current teledermatology service

1 April 2026-31 September 2027. Total contract value is £81,374.

If no:

- Is there an active or planned procurement for a teledermatology service currently under way or anticipated within the next 24 months? If yes, please provide details of the anticipated timeline.

Not applicable.

4. Teledermatology platform

A number of ICBs and/or their providers commission teledermatology platforms (e.g. SkinAnalytics, eDerma etc) so that photos can be uploaded and reviewed to assess for likelihood of skin cancers. Is a teledermatology software platform currently in use in your ICB area?

Nottingham University Hospitals NHS Trust (NUH) and Sherwood Forest Hospitals NHS Foundation Trust (SFHFT) utilise SkinAnalytics.

If yes:

- Please state the name of the teledermatology software platform or system currently in use. If more than one platform is in use across the ICB area, please list all
- Please state the start date, end date, and total contract value of the current teledermatology platform contract

For further details, please contact individual providers and how to submit a Freedom of Information request to each provider can be found on their website links below:

- Nottingham University Hospitals NHS Trust - <https://www.nuh.nhs.uk/freedom-of-information>
- Sherwood Forest Hospitals NHS Foundation Trust - [Freedom of Information | Sherwood Forest Hospitals](#).

If no:

- Is there an active or planned procurement for a teledermatology platform currently under way or anticipated within the next 24 months? If yes, please provide details of the anticipated timeline.

Not applicable.

5. Advice and Guidance

Does your ICB currently use a digital platform to support dermatology Advice and Guidance between primary and secondary care? If yes, please state the platform in use.

No, the ICB does not use a digital platform.

If you are unhappy with the way in which your request has been handled, NHS Nottingham and Nottinghamshire Integrated Care Board (ICB) has an internal review procedure through which you can raise any concerns you might have. Further details of this procedure can be obtained by contacting Lucy Branson, Director of Corporate Governance and Assurance via lucy.branson@nhs.net or by writing to FOI Team at NHS Nottingham and Nottinghamshire ICB, Sir John Robinson House, Sir John Robinson Way, Arnold, Daybrook, Nottingham NG5 6DA.

If you remain dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office (ICO), who will consider whether the organisation has complied with its obligations under the Act and can require the organisation to remedy any problems. Generally, the ICO cannot make a decision unless you have exhausted the complaints procedure provided by NHS Nottingham and Nottinghamshire ICB. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: <https://ico.org.uk/for-the-public/>.

Complaints to the Information Commissioner's Office should be sent to:

FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 123 1113 or report a concern via <https://ico.org.uk/concerns/>.

Yours sincerely

Freedom of Information (FOI) Officer on behalf of NHS Nottingham and Nottinghamshire Integrated Care Board nnicb-nn.foi@nhs.net

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the [Open Government Licence](#) (OGL) a request to re-use is not required, but the license conditions must be met. You must not re-use any previously unreleased information without having the consent of NHS Nottingham and Nottinghamshire Integrated Care Board. Should you wish to re-use previously unreleased information then you must make your request in writing (email will suffice) to the FOI Lead via nnicb-nn.foi@nhs.net. All requests for re-use will be responded to within 20 working days of receipt.